We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Hypertension With Adalat® in Combination With Other Drugs

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01118286
First Posted: May 6, 2010
Last Update Posted: June 27, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bayer
  Purpose
To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.

Condition Intervention
Hypertension Drug: Nifedipine (Adalat, BAYA1040)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: AdADOSE - Antihypertensive Treatment With Adalat® in Different Doses and Combination Therapy

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Evaluation of treatment success (lowering of blood pressure in mmHg) in adult hypertensive patients [ Time Frame: After three months ]

Enrollment: 4497
Study Start Date: January 2010
Study Completion Date: September 2011
Groups/Cohorts Assigned Interventions
Group 1 Drug: Nifedipine (Adalat, BAYA1040)
Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy
Criteria

Inclusion Criteria:

  • Previously untreated hypertensive patients starting with combination therapy containing nifedipine or
  • Insufficiently controlled hypertensive pts. receiving nifedipine as an add-on to existing non-CCB (calcium-channel-blocker) containing antihypertensive therapy

Exclusion Criteria:

  • None. Exclusion criteria are defined by contraindications and precautions as stated in the local product information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01118286


Locations
Bahrain
Many Locations, Bahrain
Egypt
Many Locations, Egypt
Jordan
Many Locations, Jordan
Lebanon
Many Locations, Lebanon
Morocco
Many Locations, Morocco
Oman
Many Locations, Oman
Pakistan
Many Locations, Pakistan
Qatar
Many Locations, Qatar
Russian Federation
Many Locations, Russian Federation
Saudi Arabia
Many Locations, Saudi Arabia
United Arab Emirates
Many Locations, United Arab Emirates
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Medical Affairs Therapeutic Area Head, Bayer Healthcare AG
ClinicalTrials.gov Identifier: NCT01118286     History of Changes
Other Study ID Numbers: 14296
AL0701 ( Other Identifier: company internal )
AdADOSE ( Other Identifier: company internal )
First Submitted: May 5, 2010
First Posted: May 6, 2010
Last Update Posted: June 27, 2012
Last Verified: June 2012

Keywords provided by Bayer:
Hypertension
Drug therapy, combination

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Nifedipine
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents
Physiological Effects of Drugs